GW&K Investment Management LLC Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)

GW&K Investment Management LLC lessened its position in Merck & Co., Inc. (NYSE:MRK) by 6.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 460,168 shares of the company’s stock after selling 32,632 shares during the quarter. GW&K Investment Management LLC’s holdings in Merck & Co., Inc. were worth $38,737,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of MRK. Titan Capital Management LLC CA acquired a new position in Merck & Co., Inc. during the 2nd quarter worth $25,000. LFA Lugano Financial Advisors SA grew its stake in Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after purchasing an additional 225 shares in the last quarter. JJJ Advisors Inc. acquired a new position in Merck & Co., Inc. during the 2nd quarter worth $27,000. Cumberland Partners Ltd acquired a new position in Merck & Co., Inc. during the 2nd quarter worth $40,000. Finally, Fusion Family Wealth LLC grew its stake in Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after purchasing an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.

MRK has been the subject of several analyst reports. Credit Suisse Group reissued a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Bank of America initiated coverage on Merck & Co., Inc. in a research note on Wednesday, October 16th. They set a “neutral” rating and a $90.00 target price for the company. Svb Leerink initiated coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They set an “outperform” rating and a $103.00 target price for the company. Leerink Swann initiated coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They set an “outperform” rating and a $103.00 target price for the company. Finally, Mizuho boosted their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. presently has an average rating of “Buy” and a consensus target price of $95.13.

Shares of NYSE:MRK traded up $0.71 on Friday, hitting $83.59. 6,053,527 shares of the company’s stock were exchanged, compared to its average volume of 10,105,755. The firm’s 50-day moving average is $84.01 and its 200 day moving average is $82.77. The company has a market capitalization of $212.31 billion, a PE ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $87.35. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion during the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Bond

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit